MJFF announced an exciting second study to test Nilotinib ( The approved drug used for Cronic Myelogenous leukemia), repurposed for people with Parkinson's. This study is called Nilo-PD. It's restricted to the USA, they're looking for 75 PEOPLE with Parkinson's, between the ages of 40 to 79, who have moderate to advanced PD (Diagnosed five+ years).
Great question! Nilo has not been approved for PD. If you're comparing it to Leukemia, the doses are far greater, therefore, more expensive. The first study Nilo reduced the buildup of alpha - synuclein. The Nilo-PD study would cost you $0. For more information contact Fox Trial Finder.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.